Relapsing Remitting Multiple Sclerosis
Links shared publicly online about this topic
Merck Seeks European License For Cladribine for relapsing remitting MS
medicalnewstoday.com — “Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes aft” View full resource at medicalnewstoday.com
Most Recently Shared on July 27, 2009 at 11:32 am By:
MedNewsToday: Merck Seeks European License For Cladribine for relapsing remitting MS: Merck Serono .. http://bit.ly/NUQkf
Stephen Harris Shares His Multiple Sclerosis Story - Relapsing-Remitting MS - Multiple Sclerosis
healthcentral.com — “When I first met Stephen on-line I was still reeling from my diagnosis of Multiple Sclerosis. I didn't know what it meant or what to do or think. One of the ways I coped was to reach out to find others who had this disease. Stephen was one of the wonde” View full resource at healthcentral.com
Most Recently Shared on June 30, 2011 at 2:21 pm By:
HealthCentral Tips Health Site
@Partinaire02 Glad to hear your positive outlook! We have a series of interviews w/ people who have MS http://bit.ly/kbg0en if ur interested
Lisa Emrich's Diagnosis Story - 10 Year Anniversary - Relapsing-Remitting MS - Multiple Sclerosis
healthcentral.com — “To celebrate MS Awareness Month, Lisa Emrich shares her story on the 10-year anniversary of the diagnosis.” View full resource at healthcentral.com
Most Recently Shared on August 26, 2011 at 2:47 pm By:
HealthCentral Tips Health Site
@SabrinaSisk31 Congratulations on your 2 year anniversery! Here's another first-hand account: http://j.mp/pt7DtI You're not alone!
FDA Advisory Committee Unanimously Recommends Approval Of Novartis Investigational Treatment FTY720 To Treat Relapsing Remitting MS
medicalnewstoday.com — “An advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form” View full resource at medicalnewstoday.com
Most Recently Shared on August 7, 2010 at 2:05 pm By:
MNT Pharma News Pharma and Health News
FDA Advisory Committee Unanimously Recommends Approval Of Novartis Investigational Treatment FTY720 To Treat Relapsing... http://mnt.to/3H7B
ALLOZYNE Announces Completion Of Phase IA Trial By AZ01, A Long Lasting Interferon For Treatment Of Relapsing Remitting Multiple Sclerosis
medicalnewstoday.com — “ALLOZYNE, Inc. announced, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatme” View full resource at medicalnewstoday.com
Most Recently Shared on January 13, 2011 at 2:05 pm By:
ALLOZYNE Announces Completion Of Phase IA Trial By AZ01, A Long Lasting Interferon ? For Treatment Of Relapsing Remit... http://mnt.to/3PWJ
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial : The Lancet
thelancet.com — “Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. By - Prof Ludwig Kappos MD, David Li MD, Peter A Calabresi MD, Paul O'Connor MD,...” View full resource at thelancet.com
Most Recently Shared on November 1, 2011 at 12:24 pm By:
Study shows ocrelizumab successfully targets immune system B cells that are implicated in multiple sclerosis http://t.co/Qn6mgzYS #Neurology
Protagen To Apply UNIarray Platform For Biogen Idec To Help Discover Biomarkers In Relapsing Remitting Multiple Sclerosis
medicalnewstoday.com — “Protagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis announced today that they will be using the UNIarray® Platform to help discover biomarkers in relapsing rem” View full resource at medicalnewstoday.com
Most Recently Shared on March 29, 2011 at 9:05 am By:
Protagen To Apply UNIarray Platform For Biogen Idec To Help Discover Biomarkers In Relapsing Remitting Multiple Sclerosis http://mnt.to/3SQy
First Oral Treatment For Highly Active Relapsing Remitting Multiple Sclerosis Provides New Choice For UK Patients Failing On Injections
medicalnewstoday.com — “The first oral treatment for multiple sclerosis (MS) has been given the green light by UK regulators and is now available in the UK. Fingolimod0.5 mg (Gilenya™) has been authorised for peopl” View full resource at medicalnewstoday.com
Most Recently Shared on April 19, 2011 at 2:59 pm By:
First Oral Treatment For Highly Active Relapsing Remitting Multiple Sclerosis Provides New Choice For UK Patient... http://bit.ly/gBGjj9
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial : The Lancet
thelancet.com — “Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. By - Prof Ludwig Kappos MD, David Li MD, Peter A Calabresi MD, Paul O'Connor MD,...” View full resource at thelancet.com
Most Recently Shared on November 1, 2011 at 7:19 pm By:
Sandeep Pulim Doctor, Health Communicator, and Physician
ocrelizumab targets immune system B cells that R implicated in MS, reduces MS-related brain lesions & disease activity http://t.co/sicBWhzd
Setbacks In Patients With Relapsing-Remitting Multiple Sclerosis Can Be Reduced If Methylprednisolone Is Added To Interferon Beta
medicalnewstoday.com — “Conclusions reported in an Article published Online first, as well as in the June edition of The Lancet Neurology, and the announcement made at the American Academy of Neurology meeting in ” View full resource at medicalnewstoday.com
Most Recently Shared on May 5, 2009 at 12:04 pm By:
MedNewsToday: Setbacks In Patients With Relapsing-Remitting Multiple Sclerosis Can Be Reduced If Me.. http://tinyurl.com/c8ccfk
FDA Advisory Committee Recommends Approval of FTY720 Fingolimod for Relapsing Remitting Multiple Sclerosis
disabled-world.com — “FTY720 (fingolimod) represents significant advance as efficacious MS oral treatment for people with relapsing remitting multiple sclerosis” View full resource at disabled-world.com
Most Recently Shared on June 12, 2010 at 10:23 pm By:
Disabled World Health Advocate and Health News
FDA Advisory Committee Recommends Approval of FTY720 Fingolimod for Relapsing Remitting Multiple Sclerosis http://ff.im/-lWlBP
ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis
news-medical.net — “ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.” View full resource at news-medical.net
Most Recently Shared on January 11, 2011 at 5:46 pm By:
ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis: ALLOZYNE, Inc. announ... http://bit.ly/enu7R9
EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis
news-medical.net — “EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).” View full resource at news-medical.net
Most Recently Shared on March 2, 2011 at 10:55 am By:
News-Medical.Net Oncology and Health News
Oncology News: EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis:... http://bit.ly/eokKUi
NHS Evidence - UK Database of Uncertainties about the Effects of Treatments (DUETs) - Daclizumab for relapsing remitting multiple sclerosis
library.nhs.uk — “The Database of Uncertainties about the Effects of Treatments (DUETs) assembles and publishes uncertainties about the effects of treatments which cannot currently be answered by referring to reliable, up-to-date systematic reviews of existing research evidence. Because inadequately evaluated treatments can do more good than harm, uncertainties about the effects of treatments must be identified and those deemed sufficiently important addressed in research.” View full resource at library.nhs.uk
Most Recently Shared on March 10, 2011 at 11:53 pm By:
DUET - Daclizumab for relapsing remitting multiple sclerosis: Monoclonal antibodies such as daclizumab could be ... http://bit.ly/fA24PK
Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis
news-medical.net — “Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has secured an exclusive option and license agreement utilizing PolyTherics' site-specific TheraPEG PEGylation technology to develop NU400, a long-acting version of Nuron's proprietary recombinant human interferon beta-1b.” View full resource at news-medical.net
Most Recently Shared on May 27, 2011 at 7:27 am By:
Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis: Nuron Biotech Inc.... http://bit.ly/muAYs7
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Lisa Emrich
Patient Advocate and Blogger, Living with Multiple Sclerosis and Rheumatoid Arthritis, Musician, Educator, and writer for HealthCentral.com
-
HealthCentral Tips
News and Views on everything health! ADD/ADHD, Mental Health, Cancer, Anxiety, Depression, Kid's Health, Sexual Health, Fitness, Chronic Pain, MS, RA etc.
-
HealthCentral Tips
News and Views on everything health! ADD/ADHD, Mental Health, Cancer, Anxiety, Depression, Kid's Health, Sexual Health, Fitness, Chronic Pain, MS, RA etc.
Advertisement
